
Alexion Pharmaceuticals, Inc. EBITDA 2011-2026 | ALXN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Alexion Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 3.11 B | 2.45 B | 1.91 B | 1.12 B | 1.12 B | 799 M | 963 M | 567 M | 454 M | 245 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.11 B | 245 M | 1.27 B |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Agenus
AGEN
|
-146 M | $ 3.27 | -1.8 % | $ 1.17 M | ||
|
Agios Pharmaceuticals
AGIO
|
-467 M | $ 29.33 | -2.98 % | $ 1.7 B | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Akebia Therapeutics
AKBA
|
24.8 M | $ 1.26 | -3.44 % | $ 324 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-21.6 M | $ 0.24 | 1.1 % | $ 5.73 B | ||
|
Aldeyra Therapeutics
ALDX
|
-35 M | $ 5.49 | 0.52 % | $ 330 M | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Alector
ALEC
|
-150 M | $ 2.26 | -7.2 % | $ 233 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Aligos Therapeutics
ALGS
|
-86.6 M | $ 7.02 | -0.21 % | $ 451 M | ||
|
Alkermes plc
ALKS
|
281 M | $ 29.32 | -2.61 % | $ 4.83 B | ||
|
Allogene Therapeutics
ALLO
|
-314 M | $ 2.57 | -7.73 % | $ 403 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 330.95 | -0.59 % | $ 43.4 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Altimmune
ALT
|
-103 M | $ 4.2 | -2.55 % | $ 298 M | ||
|
ALX Oncology Holdings
ALXO
|
-142 M | $ 2.11 | 0.09 % | $ 110 M | ||
|
Amgen
AMGN
|
14.2 B | $ 387.85 | 0.03 % | $ 209 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 20.22 | -0.05 % | $ 945 M | ||
|
Amarin Corporation plc
AMRN
|
-67.4 M | $ 13.62 | -1.3 % | $ 5.55 B | ||
|
AIM ImmunoTech
AIM
|
-19.9 M | $ 0.92 | 5.25 % | $ 44.2 M | ||
|
AnaptysBio
ANAB
|
-114 M | $ 54.61 | -0.8 % | $ 1.55 B | ||
|
Anika Therapeutics
ANIK
|
-81.2 M | $ 14.44 | 0.53 % | $ 212 M | ||
|
ANI Pharmaceuticals
ANIP
|
68.3 M | $ 75.31 | 1.91 % | $ 1.45 B | ||
|
Annexon
ANNX
|
-152 M | $ 5.38 | -3.93 % | $ 739 M | ||
|
Annovis Bio
ANVS
|
-45 M | $ 2.6 | -2.99 % | $ 23.5 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Apellis Pharmaceuticals
APLS
|
57 M | $ 20.53 | -2.05 % | $ 2.59 B | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 0.78 | -0.67 % | $ 4.25 M | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Aprea Therapeutics
APRE
|
-15.5 M | $ 0.88 | -3.71 % | $ 3.18 M | ||
|
Aptevo Therapeutics
APVO
|
-24.2 M | $ 7.28 | -0.55 % | $ 2.01 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Aquestive Therapeutics
AQST
|
-30.1 M | $ 3.99 | -0.15 % | $ 346 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-92.1 M | $ 8.11 | -1.44 % | $ 219 M | ||
|
Ardelyx
ARDX
|
-37.9 M | $ 6.32 | -3.54 % | $ 1.52 B | ||
|
Aileron Therapeutics
ALRN
|
-65 M | - | 10.36 % | $ 9.8 M | ||
|
argenx SE
ARGX
|
-349 M | $ 762.51 | -0.58 % | $ 25 B |